Dr. Giuseppe Marchesani
Profile
Dr Giuseppe Marchesani is a highly respected Clinical Biology Scientist with strong expertise in Cell Biology and Immunology. He is widely recognised for his contributions to regenerative medicine and advanced cell-based therapies. From the beginning of his career, Dr Giuseppe Marchesani focused on applying cell therapy to cardiovascular science.
During this phase, his early work concentrated on producing clinical-grade cardiomyocytes derived from adipose-derived stem cells.
Dr Marchesani believes innovation must always align with safety, ethics, and regulatory responsibility. In 2011, thereafter Dr Giuseppe Marchesani joined the Bioscience Institute in Italy. He was crucial to the development of pharma-grade manufacturing protocols for Mesenchymal Stem Cells. His work significantly supported compliance with international quality and safety standards. These protocols helped advance the clinical use of stem cell-based therapies.
Since 2014, Dr Marchesani has served as Director of Bioscience Clinic Middle East. In this role, he oversees advanced therapeutic protocol development in regenerative medicine. Dr Giuseppe Marchesani’s recent research focuses on MSC-derived exosome technologies. He has worked extensively on optimising tangential flow filtration processes. He has also adjusted the presently used chromatography techniques for higher concentrations of exosomes.
In 2022, as a milestone, his research led to the launch of a novel exosome-based product line. Dr Marchesani continues advancing pluripotent stem cell isolation and expansion techniques. These efforts support the future development of next-generation stem cell therapeutics. Since 2020, Dr Giuseppe Marchesani has served as Chief Technology Officer at Bioscience Group.
He leads all innovation, strategy and work for the cell-based technology team. He completed his Executive MBA in 2023 to gain additional leadership skills. Through his work, Dr Giuseppe Marchesani is helping drive the advancement of regenerative medicine worldwide.
